Torrent Pharma Q1 FY27: Revenue ₹4,921cr, PAT ₹566cr

Key takeaway from the quarter

Torrent Pharmaceuticals Ltd reported a strong Q1 FY27 performance, supported by India growth and the consolidation of the JB Pharma business. The company posted revenue of ₹4,921 crore, along with a net profit of ₹566 crore for the quarter. Multiple data points in the quarter highlighted sequential improvement, while year-on-year growth was boosted by the acquisition and healthy execution in domestic formulations. Broker notes from Motilal Oswal and Nomura largely retained a Neutral stance despite the beat versus estimates, citing profitability constraints from higher interest costs. The quarter also featured progress on integration and synergy capture, which has been a key focus since the JB Pharma transaction. Alongside the results discussion, the company also indicated its next board meeting date for the September quarter results.

Q1 FY27 headline financials

On the reported numbers, revenue stood at ₹4,921 crore, up 54.85% year on year and 17.25% quarter on quarter from ₹4,197 crore. Operating profit was ₹1,643 crore, rising 59.21% year on year and 27.36% sequentially from ₹1,290 crore. PBDT came in at ₹1,326 crore, up 41.21% year on year and 27.87% quarter on quarter from ₹1,037 crore. Profit before tax was ₹733 crore, up 38.56% sequentially from ₹529 crore but down 0.68% year on year. Net profit rose to ₹566 crore, showing 55.49% quarter-on-quarter growth from ₹364 crore and 3.28% year-on-year growth. Separately, one earnings summary also reported EPS at ₹14.87, and indicated profit margin at 12% versus 17% in the year-ago period due to higher expenses.

What brokers highlighted: beat, but watch interest costs

Motilal Oswal Financial Services retained a Neutral rating after what it termed a better-than-expected Q1 FY27. It put consolidated revenue at ₹4,920 crore, up 54.8% year on year and 6.4% above its estimate. EBITDA increased 58.9% to ₹1,660 crore and was 9% ahead of estimate, while the EBITDA margin expanded 90 basis points year on year to 33.8%. The gross margin improved 80 basis points year on year to 76.4%, which helped support the margin profile. Adjusted PAT was noted at ₹580 crore, up 4.1% and 9% ahead of estimate, although higher interest costs were cited as a limiter to profit growth.

India formulations: growth and market position

A key driver in the quarter was domestic formulations, where India formulations revenue grew 60% year on year to ₹2,890 crore, forming 59% of total sales. The legacy domestic business grew 19%, while JB Chem’s domestic formulations sales increased 13%. Torrent also outperformed the Indian pharma market by 700 basis points in the period referenced in the broker note, with growth attributed to price, volume and new launches. The company became the number one player in the Indian cardiac market, a position that was also linked to the integration and expanded chronic portfolio. Management reiterated expectations for double-digit FY27 revenue growth for the combined India business.

Base business vs consolidated numbers

Torrent Pharma’s base business, excluding JB Pharma, delivered revenue from operations of approximately ₹3,720 crore in Q1 FY27, representing approximately 17% year-on-year growth. Base-business EBITDA increased 20% to ₹1,240 crore. After consolidation of JB Pharma, reported revenue was ₹4,835 crore and EBITDA was ₹1,664 crore, implying an EBITDA margin of 33.8%. Consolidated gross margin was stated at 76.4%. Quarterly net sales increased 54.6% year on year and 17.1% sequentially, while EBITDA increased 61.2% year on year.

Overseas markets: US, Germany and Brazil mentions

The company’s regional commentary pointed to growth across India, Brazil, the US and Germany at 19%, 27%, 36% and 3%, respectively, for the base business. Another summary of the quarter stated Indian revenue rose 19% and US revenue grew 36%, while Germany and Brazil recorded growth of 3% and 27%, respectively. Nomura added that Brazil revenue in the first quarter was affected by channel inventory correction, and said that adjusting for this, constant-currency growth reached the mid-to-high teens as per management. Nomura forecast 17% year-on-year constant-currency growth for the second quarter.

Semaglutide and product execution updates

Torrent disclosed that generic semaglutide held a 36% combined oral and injectable market share and contributed approximately 3% of India business growth. Its Q1 FY27 revenue contribution was approximately ₹50 crore. The company also flagged that supply issues at a vendor affected approximately 20% of its semaglutide stock-keeping units. Alternative supplies were expected to begin in August 2026, which framed near-term execution for this product category.

JB Pharma integration and cost synergy trajectory

On integration, Nomura highlighted early realisation of cost synergies from the JB Pharma acquisition and modelled further sequential EBITDA margin expansion as synergies materialise. It noted that in the first quarter, JB Pharma’s EBITDA margin expanded 650 basis points year on year, driven by gross margin improvement and overhead cost synergies. Management guided for additional cost synergies in the second, third and fourth quarters of FY27. It also confirmed that synergies for the full year would exceed earlier guidance of ₹90 crore (₹900 million). Separately, the company recorded ₹21 crore in exceptional items related to the JB Pharma amalgamation, which was flagged as a factor affecting near-term comparability.

Dates to track: board meeting and conference call

Torrent Pharmaceuticals informed BSE that a board meeting was scheduled on 23 October 2026 to consider and approve audited standalone financial results and unaudited consolidated results (with limited review) for the quarter and half-year ended 30 September 2026. The company also indicated it would hold a conference call on 23 October 2026 to discuss Q2 FY27 financial results for the period ended 30 September 2026. The last earnings date referenced for Q1 FY27 was 30 July 2026, with the upcoming earnings date listed as 23 October 2026.

Snapshot table: Q1 FY27 metrics reported

Market impact and what the numbers imply

The quarter’s reported growth rate was heavily influenced by consolidation, but the base-business growth indicators were also positive, especially in India and the US. Margin commentary across broker notes converged around an EBITDA margin of 33.8% and improvement in gross margin, suggesting operating leverage and mix benefits. At the same time, interest costs were explicitly cited as a headwind, explaining why profit growth lagged revenue and EBITDA growth in some summaries. The reported profit margin decline to 12% from 17% in one earnings summary also points to cost pressures despite strong top-line expansion. For investors, the key near-term monitorables are synergy capture pace, Brazil normalisation after channel inventory correction, and execution in semaglutide amid supply constraints.

Broker positioning and forward estimates cited

Motilal Oswal said it largely maintained FY27 and FY28 estimates, forecasting a 25% sales CAGR over FY26-28E, a 31% EBITDA CAGR, and a 23% earnings CAGR. Nomura maintained a Neutral rating and set a target price of ₹4,670, based on 25 times December 2027 forecast EBITDA of ₹7,570 crore (₹75.7 billion). Nomura projected an EBITDA margin of 34.4%, an expansion of 158 basis points year on year, and said its second-quarter sales, EBITDA and PAT estimates were 2%, 5% and 5% above consensus, respectively. It also referenced Pharmarack data showing 16.3% year-on-year growth in the Indian pharmaceutical market for Torrent in the July-September quarter on a like-for-like basis after JB Pharma consolidation, compared with broader market growth of 12%.

Conclusion

Torrent Pharma’s Q1 FY27 combined strong reported growth with clear updates on integration, margins and product execution, while profit growth was moderated by interest costs and expenses. The next key catalyst is the 23 October 2026 board meeting and earnings discussion for the quarter and half-year ended 30 September 2026, along with the scheduled conference call on the same date.